Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:36:10 EDT Fri 26 Apr 2024
Enter Symbol
or Name
USA
CA



Q:ALVO - ALVOTECH - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ALVO - Q0.111.45·15.500.114.15+0.503.7248.53,4691,00814.00  14.23  14.0018.00  6.7017:56:13Apr 2415 min RT 2¢

Recent Trades - Last 10 of 1008
Time ETExPriceChangeVolume
17:56:13Q14.230.58100
17:28:02Q13.870.2235
16:40:37Q13.790.145
16:00:01Q14.150.50100
16:00:01Q14.150.5065
16:00:01Q14.150.50200
16:00:01Q14.150.504
16:00:01Q14.150.50100
16:00:01Q14.150.5010
16:00:01Q14.150.5081

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-24 04:00U:ALVONews ReleaseAlvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi(TM) (golimumab)
2024-04-19 06:10U:ALVONews ReleaseAlvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira(TM) (adalimumab)
2024-04-16 17:43U:ALVONews ReleaseAlvotech and Teva Announce U.S. FDA Approval of SELARSDI(TM) (ustekinumab-aekn), biosimilar to Stelara(TM) (ustekinumab)
2024-04-03 07:41U:ALVONews ReleaseAlvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
2024-03-22 16:15U:ALVONews ReleaseAlvotech Announces Increase in Number of Own Shares
2024-03-20 16:15U:ALVONews ReleaseAlvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
2024-03-05 16:00U:ALVONews ReleaseAlvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
2024-02-29 16:05U:ALVONews ReleaseAlvotech Appoints Interim Chief Quality Officer
2024-02-26 04:25U:ALVONews ReleaseAlvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
2024-02-23 20:15U:ALVONews ReleaseAlvotech and Teva Announce U.S. Approval of SIMLANDI(TM) (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira(TM)
2024-02-15 06:30U:ALVONews ReleaseAlvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara ‚ ® (ustekinumab)
2024-01-29 04:00U:ALVONews ReleaseAlvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia ‚ ® and Xgeva ‚ ®
2024-01-19 11:30U:ALVONews ReleaseAlvotech Provides Update on Status of ‚  Biologics License Applications for AVT02 and AVT04
2024-01-10 03:30U:ALVONews ReleaseSTADA and Alvotech secure approval for Uzpruvo, Europe ¢ € ™s first ustekinumab biosimilar to Stelara
2024-01-03 03:30U:ALVONews ReleaseAlvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea ‚ ® (aflibercept)
2023-11-29 04:00U:ALVONews ReleaseAlvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi ‚ ® and Simponi Aria ‚ ®
2023-11-28 16:15U:ALVONews ReleaseAlvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
2023-11-21 08:00U:ALVONews ReleaseAlvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET